Clinical Trial Update: Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the Chidamide-Lenalidomide-Dexamethasone (CRD) regimen in relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Chidamide (chidamide)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Peng Liu | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN